0000000000055036

AUTHOR

Eva Surmacz

showing 18 related works from this author

Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis.

2008

Abstract Background Obesity in postmenopausal women is associated with increased breast cancer risk, development of more aggressive tumors and resistance to certain anti-breast cancer treatments. Some of these effects might be mediated by obesity hormone leptin, acting independently or modulating other signaling pathways. Here we focused on the link between leptin and HER2. We tested if HER2 and the leptin receptor (ObR) can be coexpressed in breast cancer cell models, whether these two receptors can physically interact, and whether leptin can transactivate HER2. Next, we studied if leptin/ObR can coexist with HER2 in breast cancer tissues, and if presence of these two systems correlates wi…

LeptinTranscriptional Activationmedicine.medical_specialtyCancer ResearchReceptor ErbB-2Breast Neoplasmslcsh:RC254-282Breast cancerSurgical oncologyRisk FactorsInternal medicineCell Line TumormedicineGeneticsHumansObesityReceptorskin and connective tissue diseasesneoplasmsLeptin receptorbusiness.industryLeptinCarcinoma Ductal BreastReceptor Cross-Talklcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticPostmenopauseEndocrinologyOncologyImmunohistochemistryReceptors LeptinFemaleSignal transductionbusinessImmunostainingProtein BindingResearch ArticleBMC cancer
researchProduct

Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells

2009

Leptin is overexpressed in human breast tumors and is produced by breast cancer cells in response to obesity-related stimuli. The leptin promoter polymorphism Lep-2548G/A can be associated with increased leptin secretion by adipocytes and elevated cancer risk. However, molecular mechanisms underlying the link between Lep-2548G/A and breast cancer have never been addressed. Lep-2548G/A is proximal to a binding site for the transcriptional factor Sp1. Furthermore nucleolin, a transcriptional repressor, can bind Sp1 or its consensus site. Consequently, we focused on the impact of Lep-2548G/A on Sp1- and nucleolin-dependent leptin transcription in breast cancer cells. The Lep-2548G/A was identi…

LeptinChromatin ImmunoprecipitationCancer Researchmedicine.medical_specialtyGenotypeSp1 Transcription FactorBlotting WesterneducationAdipokineBreast NeoplasmsBiologyBody Mass IndexBreast cancerInternal medicineTumor Cells CulturedmedicineHumansHypoglycemic AgentsInsulinObesityRNA MessengerPromoter Regions Genetichealth care economics and organizationsPolymorphism GeneticLeptin receptorReverse Transcriptase Polymerase Chain ReactionLeptinRNA-Binding ProteinsCancerPhosphoproteinsmedicine.diseaseEndocrinologyOncologyCancer researchImmunohistochemistryBreast diseaseNucleolinhormones hormone substitutes and hormone antagonistsInternational Journal of Cancer
researchProduct

Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaPopulationBRCA1 breast cancerBreast NeoplasmsBiologyRisk AssessmentAllelotype AnalysisReference ValuesHumansAlleleeducationSicilySequence DeletionOvarian NeoplasmsGeneticseducation.field_of_studyBRCA1 ProteinHaplotypeFounder Effectlanguage.human_languagePedigreeOncologyMutationMutation (genetic algorithm)languageMicrosatelliteFemaleSicilianMicrosatellite RepeatsFounder effect
researchProduct

4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

2007

Various studies have been published in Italy regarding the different BRCA1 mutations, but only the BRCA1-5083del19 mutation is recurrent and specific to individuals of Italian descent with a founder effect on the Calabrian population. In our previous study, BRCA1-5083del19 mutation carriers were found in four index cases of 106 Sicilian patients selected for familial and/or hereditary breast/ovarian cancers. The high frequency rate of this mutation identified in the Sicilian population led us to perform haplotype analysis in all family carriers. Five highly polymorphic microsatellite markers were used (D17S1320, D17S932, D17S1323, D17S1326, D17S1325) to establish whether or not all these fa…

MaleBRCA1 gene Founder mutation Haplotype analysis Hereditary breast and ovarian cancer Sicilian patientsSettore MED/06 - Oncologia MedicaGenetic counselingPopulationDNA Mutational AnalysisGenes BRCA1Single-nucleotide polymorphismBreast NeoplasmsBiologyBRCA1 geneHaplotype analysiHumansAlleleeducationAllelotypeFounder mutationSicilyGeneticsOvarian Neoplasmseducation.field_of_studyHaplotypeHematologylanguage.human_languageFounder EffectPedigreeOncologyHaplotypesHaplotype frequencylanguageFemaleSicilianGene DeletionFounder effectGenetic counselingMicrosatellite Repeats
researchProduct

Leptin and Its Receptor are Overexpressed in Brain Tumors and Correlate with the Degree of Malignancy

2009

Although leptin and its receptor (ObR) have emerged as important cancer biomarkers, the role of the leptin system in brain tumor development remains unknown. We screened 87 human brain tumor biopsies using immunohistochemistry and detected leptin and ObR in 55.2% and 60.9% cases, respectively. In contrast, leptin and ObR were absent in 14 samples of normal brain tissue. The presence of leptin correlated with ObR with overall concordance 80.5%. The leptin/ObR system was highly expressed in glioblastomas and anaplastic astrocytomas, while lower expression of both markers was noted in low-grade astrocytomas and gangliogliomas. The association between leptin/ObR and the degree of tumor malignan…

STAT3 Transcription Factornovel biomarkermedicine.medical_specialtyBlotting WesternBrain tumorFluorescent Antibody TechniqueCell CountBiologyleptinArticlePathology and Forensic MedicineCell Line TumorInternal medicinemedicineHumansleptin receptorProtein kinase BCell ProliferationLeptin receptorBrain NeoplasmsGeneral NeuroscienceLeptindigestive oral and skin physiologyglioblastomaBrainGliomamalignant progressionCell cyclemedicine.diseaseImmunohistochemistryOncogene Protein v-aktglioblastoma; leptin; leptin receptor; malignant progression; novel biomarkerKi-67 AntigenEndocrinologyTumor progressionReceptors LeptinImmunohistochemistryCancer biomarkersNeurology (clinical)hormones hormone substitutes and hormone antagonistsSignal TransductionBrain Pathology
researchProduct

Insulin-dependent leptin expression in breast cancer cells.

2008

Abstract Pathologic conditions associated with hyperinsulinemia, such as obesity, metabolic syndrome, and diabetes, seem to increase the risk of breast cancer. Here, we studied molecular mechanisms by which insulin activates the expression of leptin, an obesity hormone that has been shown to promote breast cancer progression in an autocrine or paracrine way. Using MDA-MB-231 breast cancer cells, we found that (a) insulin stimulated leptin mRNA and protein expression, which was associated with increased activation of the leptin gene promoter; (b) insulin increased nuclear accumulation of transcription factors hypoxia inducible factor (HIF)-1α and Sp1 and their loading on the leptin promoter;…

LeptinTranscriptional ActivationCancer Researchmedicine.medical_specialtySmall interfering RNAChromatin ImmunoprecipitationSp1 Transcription FactorBlotting WesternFluorescent Antibody TechniqueBreast NeoplasmsEnzyme-Linked Immunosorbent AssayBiologyParacrine signallingPhosphatidylinositol 3-Kinasesbreast cancerInternal medicinemedicineHyperinsulinemiaTumor Cells CulturedHumansHypoglycemic AgentsInsulinRNA MessengerRNA Small InterferingAutocrine signallingLuciferasesPromoter Regions GeneticTranscription factorCell NucleusMitogen-Activated Protein Kinase 1Gene knockdownLeptin receptorMitogen-Activated Protein Kinase 3Reverse Transcriptase Polymerase Chain ReactionLeptinmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaEndocrinologyOncologyCancer researchFemalehormones hormone substitutes and hormone antagonistsCancer research
researchProduct

Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells.

2009

Both leptin and vascular endothelial growth factor (VEGF) are growth and angiogenic cytokines that are upregulated in different types of cancer and have been implicated in neoplastic progression. Here we investigated the molecular mechanism by which leptin and VEGF expression are regulated in colon cancer by epidermal growth factor (EGF). In colon cancer cell line HT-29, EGF induced the binding of signal transducer and activator transcription 3 (STAT3) to STAT3 consensus motifs within the VEGF and leptin promoters and stimulated leptin and VEGF mRNA and protein synthesis. All these EGF effects were significantly blocked when HT-29 cells were treated with an inhibitor of the phosphoinositide…

LeptinSTAT3 Transcription FactorVascular Endothelial Growth Factor ASmall interfering RNAPhysiologyColorectal cancerClinical BiochemistryNeovascularization PhysiologicEGF/PI3K/STAT3colorectal cancerchemistry.chemical_compoundPhosphatidylinositol 3-KinasesEpidermal growth factormedicineHumansLY294002Gene SilencingRNA MessengerSTAT3Promoter Regions GeneticPI3K/AKT/mTOR pathwayCell NucleusbiologyEpidermal Growth FactorChemistryLeptinangiogenic regulators VEGF leptinCell Biologymedicine.diseaseUp-RegulationVascular endothelial growth factorGene Expression Regulation NeoplasticCancer researchbiology.proteinColorectal NeoplasmsHT29 Cellshormones hormone substitutes and hormone antagonistsProtein Binding
researchProduct

Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters.

2004

Insulin receptor substrate 1 (IRS-1) is a major signaling molecule activated by the insulin and insulin-like growth factor I receptors. Recent data obtained in different cell models suggested that in addition to its conventional role as a cytoplasmic signal transducer, IRS-1 has a function in the nuclear compartment. However, the role of nuclear IRS-1 in breast cancer has never been addressed. Here we report that in estrogen receptor alpha (ERalpha)-positive MCF-7 cells, (1) a fraction of IRS-1 was translocated to the nucleus upon 17-beta-estradiol (E2) treatment; (2) E2-dependent nuclear translocation of IRS-1 was blocked with the antiestrogen ICI 182,780; (3) nuclear IRS-1 colocalized and…

Cancer Researchmedicine.medical_specialtyTranscription Geneticmedicine.medical_treatmentBlotting WesternEstrogen receptorBiologyInsulin-like growth factorInternal medicineCell Line TumorGeneticsmedicineAnimalsHumansReceptorPromoter Regions GeneticMolecular BiologyNuclear receptor co-repressor 1DNA PrimersBase SequenceReverse Transcriptase Polymerase Chain ReactionEstrogen Receptor alphaPromoterAntiestrogenPhosphoproteinsPrecipitin TestsIRS1Cell biologyProtein TransportEndocrinologyNuclear receptorReceptors EstrogenInsulin Receptor Substrate ProteinsProtein BindingOncogene
researchProduct

Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α

2007

We reported previously that the obesity hormone leptin is overexpressed in breast cancer biopsies. Here, we investigated molecular mechanisms involved in this process, focusing on conditions that are associated with obesity, that is, hyperinsulinemia and induction of hypoxia. By using quantitative real-time PCR, immunofluorescent detection of proteins and enzyme-linked immunosorbent assays, we found that treatment of MCF-7 breast cancer cells with high doses of insulin or the hypoxia-mimetic agent CoCl2, or culturing the cells under hypoxic conditions significantly increased the expression of leptin mRNA and protein. Notably, the greatest leptin mRNA and protein expression were observed und…

Transcriptional ActivationCancer Researchmedicine.medical_specialtyActive Transport Cell NucleusBreast NeoplasmsBiologymedicine.disease_causeleptinbreast cancerInternal medicineCoactivatorGene expressionTumor Cells CulturedGeneticsmedicineHumansInsulinHIFp300-CBP Transcription FactorsPromoter Regions GeneticMolecular BiologyCell NucleusRegulation of gene expressionBinding SitesLeptin receptorLeptinPromoterCobaltHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaGene Expression Regulation NeoplasticEndocrinologyhyperinsulinemiaCarcinogenesisChromatin immunoprecipitationhormones hormone substitutes and hormone antagonistsProtein BindingOncogene
researchProduct

Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast…

2007

Cross-talk between insulin-like growth factor 1 (IGF-1) and estrogen receptor alpha (ER) regulates gene expression in breast cancer cells, but the underlying mechanisms remain unclear. Here, we studied how 17-beta-estradiol (E2) and IGF-1 affect ER transcriptional machinery in MCF-7 cells. E2 treatment stimulated ER loading on the estrogen response element (ERE) in the pS2 promoter and on the AP-1 motif in the cyclin D1 promoter. On ERE, similar amounts of liganded ER were found at 1-24-h time points, whereas on AP-1, ER binding fluctuated over time. At 1 h, liganded ER was recruited to ERE together with histone acetyltransferases SRC-1 and p300, ubiquitin ligase E6-AP, histone methyltransf…

Transcription GeneticActive Transport Cell NucleusEstrogen receptorBreast NeoplasmsLigandsResponse ElementsBiochemistryCyclin D1Cell Line TumorHumansCyclin D1RNA MessengerInsulin-Like Growth Factor IHistone H3 acetylationMolecular BiologyHormone response elementbiologyEstradiolTumor Suppressor ProteinsEstrogen Receptor alphaCell BiologyUbiquitin ligaseCell biologyUp-RegulationTranscription Factor AP-1Histone methyltransferasebiology.proteinCancer researchMdm2Trefoil Factor-1Estrogen receptor alphahormones hormone substitutes and hormone antagonistsThe Journal of biological chemistry
researchProduct

TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas.

2006

The putative role of TP53 and p16INK4A tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in TP53 were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in4%(1/28) and7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutatio…

AdenomaAdenomaGenotypePhysiologyClinical BiochemistryBiologymedicine.disease_causeMethylationEpigenesis GeneticProto-Oncogene Proteins p21(ras)GenotypemedicineCarcinomaHumansEpigeneticsTP53GeneCyclin-Dependent Kinase Inhibitor p16Base SequenceSingle-strand conformation polymorphismCell BiologyMethylationmedicine.diseaseMolecular biologyCell Transformation NeoplasticMutationDisease ProgressionTumor Suppressor Protein p53Carcinogenesis
researchProduct

Nuclear and cytoplasmic interaction of pRb2/p130 and ER-β in MCF-7 breast cancer cells

2006

Estrogens exhibit important biological functions and influence several pathological processes of hormone-dependent diseases. The biological actions of estrogens require their interaction with two estrogen receptors (ER-alpha and ER-beta), which are ligand-dependent transcription factors. ER-alpha and ER-beta exhibit distinct tissue expression patterns as well as show different patterns of gene regulation. In addition, it has been suggested that ER-beta works as a counter partner of ER-alpha through inhibition of the transactivating functions of ER-alpha. For instance, ER-beta seems to play a different role in breast tumorigenesis than ER-alpha, as ER-beta decreased expression in breast canc…

OncologyCytoplasmmedicine.medical_specialtyMolecular Sequence DataEstrogen receptorBreast NeoplasmsEstrogen receptorsmedicine.disease_causeBreast cancerBreast cancerCancer stem cellCell Line TumorInternal medicinemedicineEstrogen Receptor betaHumansImmunoprecipitationGene silencingAmino Acid SequenceTranscription factorBreast cancer; Estrogen receptors; Estrogens; pRb2/130Cell NucleusRegulation of gene expressionRetinoblastoma-Like Protein p130business.industryEstrogensHematologymedicine.diseaseOncologyMCF-7Cancer researchbusinessCarcinogenesispRb2/130
researchProduct

Founder mutations in BRCA1 and BRCA2 genes

2007

BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary breast and/or ovarian cancers. The proportion of high-risk families with breast and/or ovarian cancer cases due to mutations in these tumor suppressor genes varies widely among populations. In some population, a wide spectrum of different mutations in both genes are present, whereas in other groups specific mutations in BRCA1 and BRCA2 have been reported with high frequency. Most of these mutations are prevalent in restricted populations as consequence of a founder effect. The comparison of haplotypes between families with the same mutation can distinguish whether high-frequency alleles derive f…

Genetic counselingPopulationBiologymedicine.disease_causeGermline mutationEthnicitymedicineHumansGenetic TestingeducationGenetic testingBRCA2 ProteinGeneticseducation.field_of_studyMutationmedicine.diagnostic_testBRCA1 ProteinHaplotypeHematologyPenetranceFounder EffectOncologyMutationApoptosis Regulatory ProteinsBRCA1 BRCA2 founder mutationFounder effect
researchProduct

Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer.

2007

Background: The obesity hormone, leptin, has been found to play a role in development and proliferation of normal and malignant tissues. Leptin activity is mediated through the leptin receptor (ObR) that is often expressed in different human cancer cells. Previously, we found that the expression of leptin and ObR can be stimulated by hypoxia-mimetic agents. The aim of this study was to analyze the abundance of and relationships among leptin, ObR and hypoxia-inducible factor-1α (HIF-1α, transcriptional regulator) in human colorectal cancer. Materials and methods: We investigated the expression of leptin, ObR and HIF-1 a in colorectal cancer specimens from 135 patients who underwent curative …

AdultLeptinMalemedicine.medical_specialtyColorectal cancerAdipokineReceptors Cell SurfaceInternal medicinemedicineHumansObesityReceptorAgedAged 80 and overLeptin receptorbusiness.industryLeptindigestive oral and skin physiologyHematologyMiddle Agedmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitObesityUp-RegulationGene Expression Regulation NeoplasticEndocrinologyOncologyHypoxia-inducible factorsDisease ProgressionReceptors LeptinFemalebusinessColorectal Neoplasmshormones hormone substitutes and hormone antagonistsHormoneAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.

2010

MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of different genes, including genes involved in cancer progression. A functional link between hypoxia, a key feature of the tumor microenvironment, and miRNA expression has been documented. We investigated whether and how miR-20b can regulate the expression of vascular endothelial growth factor (VEGF) in MCF-7 breast cancer cells under normoxic and hypoxia-mimicking conditions (CoCl(2) exposure). Using immunoblotting, ELISA, and quantitative real-time PCR, we demonstrated that miR-20b decreased VEGF protein levels at 4 and 24 h following CoCl(2) treatment, and VEGF mRNA at 4 h of treatment. In addition, miR-20b reduce…

STAT3 Transcription FactorVascular Endothelial Growth Factor ATime FactorsPhysiologySettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationBreast NeoplasmsBiologyTransfectionchemistry.chemical_compoundmir20b VEGFCell Line TumormicroRNAHumansSTAT3Promoter Regions GeneticG alpha subunitRegulation of gene expressionTumor microenvironmentBinding SitesCell BiologyTransfectionCobaltHypoxia-Inducible Factor 1 alpha SubunitMolecular biologyCell HypoxiaVascular endothelial growth factorGene Expression Regulation NeoplasticMicroRNAsHIF1Achemistrybiology.proteinFemaleRNA InterferenceSignal TransductionJournal of cellular physiology
researchProduct

Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.

2006

Abstract Purpose: Recent in vitro studies suggested that the autocrine leptin loop might contribute to breast cancer development by enhancing cell growth and survival. To evaluate whether the leptin system could become a target in breast cancer therapy, we examined the expression of leptin and its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium. We also studied whether the expression of leptin/ObR in breast cancer can be induced by obesity-related stimuli, such as elevated levels of insulin, insulin-like growth factor-I (IGF-I), estradiol, or hypoxic conditions. Experimental Design: The expression of leptin and ObR was examined by immunohistochemistry…

LeptinCancer ResearchER-BETAmedicine.medical_treatmentHYPOXIA-INDUCIBLE FACTOR-1NeoplasmsTumor Cells CulturedBreastInsulin-Like Growth Factor Iskin and connective tissue diseasesReceptorAged 80 and overEstradiolIGF-I RECEPTORCELL-LINEReverse Transcriptase Polymerase Chain ReactionLeptindigestive oral and skin physiologyCarcinoma Ductal BreastMiddle AgedMetastatic breast cancerINSULINCell HypoxiaESTROGENOncologyDisease ProgressionIGF-I RECEPTOR; HYPOXIA-INDUCIBLE FACTOR-1; OB GENE; GROWTH-FACTOR; CELL-LINE; ER-BETA; ESTROGEN; ALPHA; INSULIN; MCF-7Receptors LeptinFemaleOB GENEhormones hormone substitutes and hormone antagonistsAdultmedicine.medical_specialtyGROWTH-FACTORBreast NeoplasmsReceptors Cell SurfaceBreast cancerInternal medicinemedicineBiomarkers TumorHumansObesityAutocrine signallingAgedLeptin receptorbusiness.industryInsulinmedicine.diseaseALPHAEndocrinologyTumor progressionCase-Control StudiesMCF-7business
researchProduct

BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.

2007

PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and familial Breast Cancer (BC) and/or Ovarian Cancer (OC) in patients from Southern Italy (in the region of Sicily) and to identify a possible association between the higher frequency of BRCA1 mutations and a specific familial profile. EXPERIMENTAL DESIGN: A consecutive series of 650 patients with BC and/or OC diagnosed between 1999 and 2005 were recruited from the Southern Italian region of Sicily, after interview at the "Regional Reference Centre for the Characterization and Genetic Screening of Hereditary Tumors" at the University of Palermo. Genetic counselling allowed us to recruit a total…

AdultMaleCancer ResearchGenetic counselingDNA Mutational AnalysisBreast NeoplasmsBiologymedicine.disease_causeGermlineBreast cancermedicineHumansGenetic Predisposition to DiseaseGenetic TestingGenetic testingAgedGeneticsOvarian NeoplasmsMutationPolymorphism Geneticmedicine.diagnostic_testBase SequenceBRCA1 ProteinBRCA1 Genetic testing Breast cancer Ovarian canceCancerMiddle Agedmedicine.diseasePedigreeOncologyItalyMutationFemaleAge of onsetFounder effectBreast cancer research and treatment
researchProduct

TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma

2005

ToprospectivelyevaluatetheprognosticsignificanceofTP53,H-,K-,andN-Rasmutations,DNA-ploidyandS-phasefraction(SPF) in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was 71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed byflow cytometric analyses. Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had triplemutations.Intotal,46TP53mutationswereobserved.Themajority(41%)oftheseoccurinexon5(19/46),…

Geneticsmedicine.medical_specialtyMutationPhysiologyClinical BiochemistrySingle-strand conformation polymorphismCell BiologyBiologyTp53 mutationLaryngeal squamous cell carcinomamedicine.disease_causeGastroenterologyExonInternal medicinemedicineS-Phase FractionGeneDna ploidyJournal of Cellular Physiology
researchProduct